# IMMUNOGENIC CANCER ENGINEERING THERAPEUTICS LLC: Development of MCL 1-Targeting Antibody–Drug Conjugates for Cancer Therapy

**Lab Budget Score:** 55/100

| Field | Value |
|---|---|
| Organization | IMMUNOGENIC CANCER ENGINEERING THERAPEUTICS LLC |
| Location | ENGLEWOOD CLIFFS, NJ |
| Project | Development of MCL 1-Targeting Antibody–Drug Conjugates for Cancer Therapy |
| Project number | 1R41CA314855-01 |
| Mechanism | R41 |
| Institute | National Cancer Institute |
| Award | $412,351 |
| Awarded | 2026-09-08 |
| Project period | 2026-09-08 to 2027-08-31 |
| UEI | R7CZDKCFSFQ2 |

## Why this score
- Award of $400K or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11409749). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.